The Webinar Will Begin Shortly



Questions/Comments: Share questions and comments in the chat window on the right side of your screen. Questions will be reviewed during the Q&A period.



Closed Captioning: https://bit.ly/3xK0Al1



Zoom Technical Support: +1.888.799.9666 ext.2 or <u>support.zoom.us/hc/en-us</u>



Feedback: Let us know what you thought of this presentation: https://bit.ly/3NfuauT



Join the Conversation: @ncats_nih_gov | #NCATSsbir



Using and Saving Chat

- Throughout the webinar, we will share useful links and information through the chat box in your Zoom desktop toolbar. This is usually at the top, bottom, or side of the page. Please open the chat box at this time if you wish to view and capture the links.
- To save the chat, you should have **chat cloud storage** enabled on your Zoom account.
 - To save the chat manually, click on the chat icon
 - At the bottom of the chat box, click the three dots (ellipsis) *** above the text entry line and click Save Chat.
 - This will save your chat record to your local Zoom recording location on your computer. The default Documents folder is Zoom/Folder [Meeting name, date, time]
 - If chat cloud storage is not enabled, you may be able to turn it on by following the instructions on the Zoom Support page at https://support.zoom.us/hc/en-us/articles/115005516426.
- Please be sure you have the most up-to-date version of Zoom. Go to https://zoom.us/download to get the latest version.





Hosts

NCATS

COLLABORATE, INNOVATE, ACCELERATE,

NCATS Office of Strategic Alliances

ncats.nih.gov/smallbusiness

The SBIR and STTR programs support NCATS' mission to transform the translational science process so that new treatments and cures for disease can be delivered to patients more efficiently. These programs serve as an engine of innovation, offering grants, contracts and technical assistance to small businesses and research organizations focused on advancing translational research and technologies that will improve disease prevention, detection and treatment.



NHLBI Small Business Program

https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/small-business-program

The National Heart, Blood, and Lung Institute is the leader in the prevention and treatment of heart, lung, blood, and sleep disorders. The institute works to promote the prevention and treatment of heart, lung, and blood disorders and improve the overall health of all individuals so they can live longer and healthier lives. Their main goals are to advance scientific discoveries, improve public health and fund groundbreaking research.



XLerator Network

https://xleratornetwork.com/

The XLerator Network is led by XLerateHealth in partnership with Academic Lead, the University of Kentucky. XLerateHealth has worked with over 200 early-stage health startup companies and has over 300 mentors and coaches. The network has over 25 participating academic universities that can provide resources such as health systems, payers, entrepreneurial education programs, labs, co-working spaces and more.



nia.nih.gov/sbir

Featured Speakers



Stephanie Davis, Ph.D.
Small Business Program
Coordinator
National Heart, Blood, and
Lung Institute



Eugene Krentsel, Ph.D.

Chief Scientific Officer and Vice
President – Strategic
Partnerships and Alliances
XLerateHealth



Almesha L. Campbell, Ph.D.

Assistant Vice President for
Research and Economic
Development
Jackson State University



Meena U. Rajagopal, Ph.D.
Program Officer
Office of Strategic Alliances
National Center for Advancing
Translational Sciences
National Institutes of Health



Monique LaRocque, м.р.н.
Executive Vice President
Ogilvy Health | FKH
MODERATOR





Agenda

Introductions and Objectives

NCATS SBIR & STTR Programs

- Program Overview
- Opportunities and Resources

NHLBI SBIR & STTR Programs

XLerator Network

EnRICH

Moderated Q&A

 Please use the Q&A function to submit questions at any time during the presentation







Meena U. Rajagopal, Ph.D.

Program Officer
Office of Strategic Alliances
National Center for Advancing Translational Sciences
National Institutes of Health

What Does the National Center for Advancing Translational Sciences (NCATS) Do?

1 of 27

Institutes and Centers at the National Institutes of Health (NIH). Conducts and supports research on the science and operation of translation to allow more treatments to get to more patients more quickly.





Focuses on what is common across diseases and the translational process.

Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public — from diagnostics and therapeutics to medical procedures and behavioral changes.





Translational science is the field of investigation focused on understanding the scientific and operational principles underlying each step of the translational process.

NCATS

TRANSLATIONAL SCIENCES



NCATS Scientific Initiatives

Clinical Translational Science

- Clinical and Translational Science Awards
- Rare Disease Clinical Research Network
- New Therapeutic Uses program


Preclinical Translational Science

- NCATS Chemical Genomics Center
- Therapeutics for Rare and Neglected Diseases program
- Bridging Interventional Development Gaps program

Re-engineering Translational Sciences

- Toxicology in the 21st Century
- Microphysiological Systems (Tissue Chip) program
- Office of Rare Diseases Research


SBIR and STTR: One of the Largest Sources of Early-Stage Financing







The Benefits

NCATS SMALL BUSINESS PROGRAMS (SBIR/STTR)







Projects undergo NIH's rigorous scientific peer review process, which awardees leverage to attract other funding and collaborations.



SBIR and STTR Critical Differences

	SBIR	STTR
Partnering Requirement	Permits partnering	Requires a non-profit research institution partner (e.g., university)
Work Requirement	Guidelines: May outsource 33% (Phase I) 50% (Phase II)	Minimum Work Requirements: 40% small business 30% research institution partner
Principal Investigator	Primary employment (>50%) must be with the small business	PI may be employed by either the research institution partner or small business

Award is always made to the small business



NIH SBIR/STTR Is a Three-Phase Program



Phase I Feasibility Study

Budget Guide: \$275,766 for SBIR and STTR (\$325K Waiver) **Project Period:** 6 months (SBIR);

1 year (STTR)

Phase II Full Research/R&D

\$1,838,436 for SBIR and STTR, over two years *(\$2M)*

Fast Track combines Phase I and Phase 2 Direct to Phase 2 – allows to skip Phase 1

Phase IIB Competing Renewal/R&D

Clinical R&D; Complex Instrumentation/to FDA Funding Varies (~\$1M per year) for up to 3 years

Phase III Commercialization

NIH, generally, not the "customer" Consider partnering and exit strategy



Funding Overview

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are some of the largest sources of early-stage capital for innovative small companies in the United States. These programs allow U.S.-owned and operated small businesses to engage in federal research and development (R&D) that has a strong potential for commercialization.

Omnibus Solicitation

- Investigator-initiated grant funding
- Standard Deadlines: April 5, September 5, January 5
- PHS 2022-2 Omnibus Solicitation grants are now available

Grant Solicitations in Targeted Areas

- Grant to advance a particular technology/research area
- Due dates may vary

Contract Solicitation

- Contract opportunity to advance areas of high research interest
- Typically due in October or November



Translational Science and Research Areas of Interest

SBIR and STTR programs support NCATS' mission to transform the translational science process so that new treatments and cures for disease can be delivered to patients more efficiently.

TOPICS OF INTEREST

- 1. Preclinical Drug Discovery & Development
- 2. Biomedical, Clinical & Health Research Informatics
- 3. Clinical, Dissemination & Implementation Research

2022-2023 DEADLINES:

September 6
January 5
April 5

Targeted Funding Opportunities for 2022

- Development of Highly Innovative Tools and Technology for Analysis of Single Cells
 - SBIR: PA-20-047 (R43/R44 Clinical Trial Not Allowed)
 - STTR: PA-20-025 (R41/R42 Clinical Trial Not Allowed)
 - Next Deadline: Sep 6, 2022
- Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health
 - NOT-EB-21-001
 - Next Deadline: Sep 6, 2022
- Notice of Special Interest (NOSI): Innovative Technologies for Research on Climate Change and Human Health (Clinical Trial Optional)
 - SBIR: NOT-ES-22-010
 - STTR: <u>NOT-ES-22-009</u>
 - Next Deadline: Sep. 6, 2022
- NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
 - SBIR: RFA-HL-23-008
 - Next Deadline: Feb. 28, 2023



Application Process Timeline

Due Dates	Scientific Review	Council Review	Award Date (Earliest)
SEPTEMBER 5	OCTOBER/NOVEMBER	JANUARY/FEBRUARY	MARCH/APRIL
JANUARY5	FEBRUARY/MARCH	MAY/JUNE	JULY
APRIL5	JUNE/JULY	AUGUST	SEPTEMBER OR DECEMBER



Special Designations





- Encouraging participation in innovation and entrepreneurship by socially and economically disadvantaged small businesses (SDB) and women-owned small businesses (WOSB).
- What is a <u>Socially and Economically Disadvantaged Small Business</u> (SDB)?
 - The firm must be 51% or more owned and control by one or more disadvantaged person or persons.
 - The disadvantaged person or persons must be socially disadvantaged and economically disadvantaged.
 - The firm must be small, according to SBA's <u>size standards</u>.
 - Small businesses must self-certify by registering in the <u>System for Award</u> <u>Management</u>.
- What is a <u>Women-Owned Small Business</u> (WOSB)?
 - A firm must be at least 51% owned and controlled by one or more women, and primarily managed by one or more women (who must be U.S. citizens).
 - The firm must be "small" in its primary industry in accordance with SBA's size standards for that industry.
 - SBCs self-certify on the Sam.gov.



APPLICANT ASSISTANCE PROGRAM (AAP)

AAP is a FREE Application preparation ASSISTANCE program.

PROGRAM GOAL

Provide a **mentor** for applicants with great technology, but little NIH experience and limited NIH experience in their network.

Application period: closed

Please continue to check for updates

https://sbir.cancer.gov/aap



Phase I SBIR/STTR application preparation support and review

Specific Aims page review and advice

Submission process coaching



Grant writer

Research plan development

Small business registration or NIH application submission services



Administrative Supplements to Promote Diversity (PA-21-345)

- Provides financial support for SBIR/STTR awardees to hire early-career scientists to enhance the diversity of the NIH-supported workforce
- Allows candidate to receive
 - Entrepreneurial training
 - Scientific training
 - Real-world experience
- Covers the following expenses
 - Salary Support
 - Travel
 - Supplies
- Eligibility Criteria
 - Must have an active SBIR/STTR award
 - Candidate <u>must</u> be a U.S. Citizen or a permanent resident





I-Corps at NIH™ (PAR-22-073)

- Launched at the NIH in 2014 as a program based on the Lean Startup Methodologies
- Promotes customer discovery experience by requiring participants to conduct ~100 interviews over eight weeks
 - Content from interviews helps refine proposed business model
 - "You cannot commercialize something that nobody wants
- Open to current Phase I and early stage Fast-Track SBIR/STTR awardees
- Two receipt dates per year
 - Next due date November 15th, 2022
- Selected companies may receive up to \$55K for course registration and travel expenses





NCATS Additional Resources: Technical and Business Assistance (TABA) Program

- Applicants can request additional funding for assistance making better technical decisions, solving technical problems, minimizing risks, and developing and commercializing new products
 - Phase I has a cap of \$6,500 per year.
 - Phase II has a cap of \$50,000 for the life of the project.
- TABA supports companies in areas critical to success in the competitive health care marketplace, such as access to technologies or support on product sales, intellectual property protections, market research, and planning





TABA Needs Assessment for Phase I SBIR/STTR

About the Program: The NIH TABA Program helps small businesses identify and address their most pressing product development needs. The Needs Assessment Report provides a FREE, third party, unbiased assessment of your project's progress in four technical and business areas that are critical to success in the competitive healthcare marketplace:

- Market Needs/Competitive Advantage
- Intellectual Property/Barriers to Entry
- Business Model Profitability
- Manufacturing, Regulatory, and/or Clinical Plan

Eligibility: Must be a Phase I NIH SBIR or STTR (grant, contract, or Fast-Track)

- Is active or was active within the past two years AND
- Was not awarded TABA funding within the Phase I award budget AND
- Has not already received a TABA Needs Assessment Report or NICHE Assessment for the same Phase I project

Applications are accepted on a monthly basis.





Crossing the "Valley of Death" with the NCATS Therapeutic Development Team



- Medicinal chemistry lead optimization
- Evaluation of functional activity, potency, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy
- Biomarker development
- Definition and optimization of dose and schedule for in vivo activity
- Development and implementation of pharmacological assays
- Chemical and biologics process research and development
- Manufacturing of bulk substance (GMP and non-GMP)
- Development of suitable formulations
- Development of analytical methods
- Production and stability studies of dosage forms
- Range-finding initial toxicity
- Investigational New Drug (IND)-directed toxicology, with correlative pharmacology and histopathology
- Planning of clinical trials (Phase 1 and/or Phase 2)
- Regulatory and IND filing support
- Natural history and patient-finding studies

NCATS Additional Resources: Bridging Interventional Development Gaps (BrIDGs)

Model: Collaboration between Division of Preclinical Innovation (DPI) and extramural labs (Formerly NIH-RAID Program)

Projects

- Enter with clinical candidate identified
- Any disease eligible
- Gap analysis followed by data generation using DPI resources and expertise to generate data necessary for IND filing
- Exit at or before IND
- Milestone driven
- Therapeutic modalities: small molecules, peptides, oligonucleotides, gene therapy, antibodies, recombinant proteins

Eligible Applicants

 Academic (U.S. and Ex-U.S.), Non-Profit, SBIReligible businesses





NCATS Additional Resources: Therapeutics for Rare and Neglected Diseases (TRND) Program

Model: Comprehensive drug development collaboration between DPI and extramural labs with disease-area/target expertise

Projects

- May enter at various stages of preclinical development
- Disease must meet FDA orphan or WHO neglected tropical disease criteria
- Taken to stage needed to attract external organization to adopt to complete clinical development/registration, max Phase 2a
- Milestone driven
- Therapeutic modalities: small molecules, proteins, peptides, oligonucleotides, gene therapy, antibodies, recombinant proteins
- Aims to de-risk technology and develop new generally applicable platform technologies and paradigms

Eligible Applicants


- Academic, Nonprofit, Government Lab, Biotech/Pharma
- Ex-U.S. applicants accepted





TRND/BrIDGs Project De-Risking Model

MINIMUM TIME AND FUNDING; MAXIMUM IMPACT





Connect with NCATS



Website: ncats.nih.gov



Facebook: facebook: facebook.com/ncats.nih.gov



Linkedin: linkedin.com/company/nih-ncats/



Twitter: twitter.com/ncats nih gov



YouTube: youtube.com/user/ncatsmedia



E-Newsletter: ncats.nih.gov/enews



Listserv: bit.ly/1sdOI5w






Stephanie Davis, Ph.D.

Small Business Program Coordinator
National Heart, Blood, and Lung Institute
National Institutes of Health

The NHLBI Small Business Program

Innovative and commercially-promising products to prevent, treat and diagnose heart, lung, blood, and sleep (HLBS)-related diseases

Technologies Funded by NHLBI SBIR/STTR Program



~\$120M

Approximate annual non-dilutive funds

~312

Active projects



NHLBI Mission Space



Heart

- Arrhythmias
- Atherothrombosis
- Chronic Heart Failure
- Congenital Heart Defects
- Coronary Artery Disease
- Hypertension

Lung

- •Acute Respiratory Distress Syndrome
- •Asthma
- •Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- •Fibrotic Lung Disease
- •Pulmonary Hypertension





Blood

- Bleeding Disorders
- Anemia
- Myeloproliferative Disorders
- Sickle Cell Disease
- Thrombotic Disorders

Sleep

- Circadian Disorders
- Insomnia
- Obstructive Sleep Apnea
- Sleep-Disordered Breathing





NHLBI Targeted Funding Opportunity Announcements

Funding Opportunity	FOA#
Phase IIB Bridge Awards	> RFA-HL-23-009
Phase IIB Small Market Awards	> RFA-HL-23-008
SBIR/STTR Commercialization Readiness Pilot (CRP) Program	▶ PAR-20-129▶ PAR-20-130
Innovations for Healthy Living SBIR RFA	> RFA-MD-22-004
HEAL Initiative: Technologies Directed at Enhanced Pain Management	 ▶ RFA-NS-20-008 ▶ RFA-NS-20-009 ▶ RFA-NS-20-010 ▶ RFA-NS-20-011
NOSI: Innovative Diagnostic Technology for Improving Outcomes for Maternal Health I-Corps at NIH™	➤ NOT-EB-21-001➤ PAR-22-073
NOSI: Innovative Technologies for Research on Climate Change and Human Health	NOT-ES-22-009NOT-ES-22-010

Concept to Clinic: Commercializing Innovation Program (C3i)

- The NIBIB C3i program provides medical device innovators with the tools and frameworks that are required to commercialize their technologies
- Validation/Execution
 - Twenty-four (24) weeks of entrepreneurial training
 - Open to SBIR/STTR and non-SBIR/STTR grantees
 - Due date August 5th, 2022





Phase IIB Small Market Award

The primary indication of the product under development should:

- Address a rare disease as defined in the Orphan Drug Act Amendment of 1984
- Qualify as a Humanitarian Use Device
- Targeted at young pediatric populations

Provides up to \$3M of funding over three years

1:3 Matching Funds Expected

NCATS will co-fund awards with NHLBI

Up to \$500K each year

Next Receipt Date: February 28th, 2023



Office of Translational Alliances and Coordination Programs and Resources

Academic Innovation

The Innovation Office helps the innovator navigate the pathway from discovery to product with high success rates. Academic researchers will directly benefit via product definition and preclinical work support.


Academic Community

Small Business Innovation

Small Businesses will benefit directly from the Innovation Office's professional support, funding, and supplement programs to enable the acceleration of small business privatized funding and venture capitalists and investor partnerships.

Innovator Support

Both academic and small business innovators will benefit from mentor and product development support via scientific, business, and investor expertise built upon years of experience and relevant knowledge to direct innovators towards commercialization and further funding.





Advisory Experts at NHLBI

Gautam Prakash

Renée Arnold



Intellectual Property
Advisor



Steve Flaim

Investor-In-Residence



Kwame Ulmer

Entrepreneur in Residence



Kimberly Martin

Entrepreneur in Residence

Health Economics & Reimbursement

Entrepreneur in

Residence

Intellectual Property

Investing

Regulatory

Clinical Trials





Eugene Krentsel, Ph.D.

Chief Scientific Officer and Vice President
Strategic Partnerships and Alliances
XLerateHealth



Dr. Eugene Krentsel, Chief Scientific Officer, XLerateHealth

Xlerator Network's EDI Resources

June 23, 2022

Funded by NIGMS Grant 1UT2GM130174




















https://xleratornetwork.com/

https://xleratehealth.com/

XLerator *Network*





XLerateHealth aims to cultivate and grow impactful healthcare innovation in the Midwest, Southeast, and other areas of the country where great innovation often goes unrecognized and underfunded

- Healthcare accelerator founded in 2012 (Louisville, KY)
- Steve Blank's Lean Startup Methodology
- Bootcamp (12 weeks) & Intersession (virtual) programs
- Mentoring & coaching (hundreds of mentors & subject matter experts nationwide)





*XLerate***Health**

Puerto Rico



- University of Puerto Rico Medical Sciences Campus
- Ana G. Mendez University System
- Ponce Health Sciences University

Arkansas



 University of Arkansas for Medical Sciences

Mississippi



Jackson State University

Louisiana



- LSU Health Sciences
- Southern University

Kentucky



- · University of Louisville
- Eastern Kentucky University
- Western Kentucky University
- · Northern Kentucky University
- Murray State University
- · Morehead State University

South Carolina



- · Coastal Carolina University
- Clemson University
- Winthrop University
- Benedict College

West Virginia



Marshall University




Entrepreneurial Programs & Training



Talent Network



Webinars & Podcasts



Funding Programs



Diversity Programs















- Regulatory Pathways for Phase I SBIR
- Navigating the FDA
- Drug Repurposing #1
- Drug Repurposing #2
- Tech Transfer 101: Part 1
- Tech Transfer 101: Part 2
- Tech Transfer 101: Part 3
- FDA's CDRH: Accelerating Upstream Medical Device Innovation









XLN Signature Diversity Programs







Engaging **R**esearchers and Innovators for **C**ommercialization at **H**BCUs


Engaging **T**echnologists and **R**esearchers from **U**nderrepresented **S**chools for **T**ranslation

Entrepreneurial **G**rowth and **A**cceleration with **G**ender **E**quity

EnRICH Program







- 1. 10-week virtual innovation harvesting and preaccelerator program
- 2. Offered to all Historically Black Colleges and Universities (HBCU) colleges
- 3. The goals of the program are:
- Education centered around technology transfer, entrepreneurial/lean startup mindset and growing a sustainable business;
- Idea acceleration where participants will compete to develop and pitch their healthcare innovation for IP protection, prize money and advancement toward additional commercialization programs.



Forbes

Most Relevant Most Recent All Time >

7 hours ago

Accelerator XlerateHealth Partners With Jackson State **University And University Of Kentucky To Bolster Healthcare Innovation At HBCUs**

The EnRICH program will help commercialize healthcare ideas by students and staff at historically Black colleges and universities.



By Jaynay Johnson Contributor



EnTRUST

Engaging Technologists and Researchers from Underrepresented Schools for Translation



Impact

Impact equity, diversity and inclusion in innovation



Train

Train faculty, advanced graduate students and clinicians at HSIs



Resource

Provide resources to evaluate, develop and validate the commercial potential of new life and bioscience innovations



Life Science Focused Accelerator Program for Hispanic Serving Institutions

Piloted in 2021
Program fully launched January 2022





Accelerating the commercialization of research and technologies being developed in Puerto Rico's

Hispanic Serving Institutions (HSIs)











SBIR/STTR Readiness Program

for HBCUs and Minority Entrepreneurs











Funded by SBA Catalyst AWARD

XLerateHealth













SBIR/STTR Readiness Program

XLerator *Network*

for HBCUs and Minority Entrepreneurs

Program launched March 2022












Janus Health Solutions





Week 5















Grant Muhoozi Warner, Dir of Innovation, Howard University

Different funding agencies' approaches to SBIR/STTR & the reviewer's perspective Eugene Krentsel, CSO, XLerateHealth

Week 3 Forming an entity, securing IP ^ identifying talent
Jeni Al Bahrani, Director of the Center for
Entrepreneurship, Transylvania University

Week 4

Researcher's perspective and budget preparation
Paresh Chandra Ray, Professor at Jackson State
University

Erienne Olesh, Executive Director of Faculty and Student Innovation, West Virginia University

Overview of expectations & helping participants frame how to move forward

Almesha Campbell, Associate Vice President, Jackson State University

XLeratorNetwork

```
entrepreneurial
                                   partners
                  related Southeast
             participating expertise
                                       technologies
              IP through help include innovators
programming
           startup including
biomedical Ventures regions
practices
XLerator
                                        accelerators
   support
     create
     access customers
                                                companies
          offered platform licensing example Beneficiaries
                          development network services
  materials institution
       online academic
                       education
      transfer Plan
             content commercialization
           technology research
```

Word It Out

eugene@xleratehealth.com

https://xleratornetwork.com/



Almesha L. Campbell, Ph.D.

Assistant Vice President for Research and Economic Development Jackson State University



Engaging Researchers and Innovators for Commercialization at HBCUs (EnRICH)

Presented by:

Almesha L. Campbell Executive Director

The program, "Engaging Researchers and Innovators for Commercialization at HBCUs" (EnRICH), is led by Jackson State University, with support from leadership at XlerateHealth and the University of **Kentucky Office of Technology** Commercialization







The goals of the program are to impact equity, diversity, and inclusion in innovations, and train faculty and students at HBCUs to critically evaluate the commercial potential of new healthcare innovations.




As a Carnegie classified High Research Activity university, Jackson State University (JSU) is designated as the Urban University of Mississippi. Located in Jackson, MS, JSU was established in 1877.

The mission of Jackson State University, an HBCU and comprehensive urban research university, is to provide quality teaching, research and service at the baccalaureate, masters, specialist, and doctoral levels to diverse populations of students and communities using various modalities to ensure that they are technologically-advanced, ethical, global leaders who think critically and can address societal problems and compete effectively.

ELIGIBILITY

EnRICH Eligible Schools

- 1 AR Arkansas Baptist College
- 2 AR Philander Smith College
- 3 AR University of Arkansas at Pine Bluff
- 4 AR Shorter College- North Little Rock
- 5 DE Delaware State University
- 6 KY Kentucky State University
- 7 KY Simmons College
- 8 LA Dillard University
- 9 LA Grambling State University
- 10 LA Southern University & A&M College
- 11 LA Xavier University of Louisana
- 12 LA Southern University New Orleans
- 13 LA Southern University-Shreveport
- 14 MS Alcorn State University
- 15 MS Jackson State University
- 16 MS Mississippi Valley State University
- 17 MS Rust College
- 18 MS Tougaloo College
- 19 MS Coahoma Community College
- 20 MS Hinds Community College-Utica
- 21 OK Langston University
- 22 SC Allen University
- 23 SC Benedict College
- 24 SC Claflin University
- 25 SC Morris College
- 26 SC South Carolina State University
- 27 SC Voorhees College
- 28 SC Clinton College
- 29 SC Denmark Technical College
- 30 WV Bluefield State College
- 31 WV West Virginia State University



Program Outline

- Week 1- Introductions; Invention Disclosures and Intellectual Property
- Week 2 Understanding How TTOs Work/ Evaluations (Patent Landscape Search/
- Market Assessment)
- Week 3 Introduction to Lean LaunchPad Methodology
- Week 4 Customer Discovery Best Practices
- Week 5 Pains/Gains and MVP
- Week 6 Lessons Learned Presentations/Business Model Canvas Overview
- Week 7 Leveraging TTOs (and other Support Services)
- **Week 8 -** Intro to Startup Formation/ Funding Types
- Week 9 Perfect your Pitch
- Week 10 Pitch Competition



SELECTION CRITERIA

- Selected applicants will be chosen based on:
 - (1) the potential for validation of their concept,
 - (2) the potential for impact from their stated goals, and
 - (3) the clarity and effectiveness of the video presentation.

Participants: Over 8 HBCUs have participated; over 50 participants; both faculty and students; 2 SBIR submissions; 3 IP disclosures.

Instructors

Coaches experienced in entrepreneurial ventures, programs and education.

- Almesha L. Campbell, Ph.D.- Principal Investigator for the JSU I-Corps Site Program and the Director for Technology Transfer and Commercialization at Jackson State University;
- Atty. **Angela Grayson** dynamic speaker and highly skilled patent attorney
- **Grant Warner,** Ph.D., National I-Corps Coach and Director of Innovation & Entrepreneurship and Associate Professor of Mechanical Engineering at Howard University.
- Marc Filerman, Regional I-Corps Instructor and CEO of Life Sciences at the German Accelerator



Almesha Campbell, PhD





Angela J. Grayson, CIPP/US, CLP





Grant Warner, Ph.D.





Marc Filerman



KEY TEAM MEMBERS

Special thanks to a dynamic team:

Jackson State University

• Almesha L. Campbell, Ph.D. — Executive Director, EnRICH

University of Kentucky

- Ian McClure, J.D., LL.M. Executive Director, UK Office of Tech Commercialization
- Taunya Phillips Senior Associate Director, New Ventures & Alliances (UK OTC)


 <u>XLerateHealth</u>
- Eugene Krentsel, Ph.D. Chief Scientific Officer, XLerateHealth
- Jackie Wilmott, MSN, MBA CEO/Co-founder, XLerateHealth











SPONSORSHIP

- Curriculum Development and Delivery
- Mentoring Prizes
- Patent expenses
- Entry fees for accelerator programs
- Culminating Event
- Program sustainability, ensuring the longevity of EnRICH and its impact







PROMOTION

Xleratornetwork.com/EnRICH



EnRICHprogram



EnRICHprogram



Jan 11, 2021, 02:23pm EST | 61 views

Accelerator XlerateHealth Partners With Jackson State University And University Of Kentucky To Bolster Healthcare Innovation At HBCUs



For(bes) The Culture Contributor Group ©

I'm the Founder of Teen Talk and cofounder of The Black Brain Campaign



The deadline to apply for EnRICH's second cohort is January 15, 2021. GETTY

Healthcare innovation, particularly in underserved communities

disproportionately affected by the ongoing health crisis, has been crucial. Part of

Get unlimited access to the most trusted source for



EnRICH is a human health-focused innovation harvesting and commercialization "pre-accelerator" program for faculty and students at HBCUs

> Apply today at xleratornetwork.com/EnRICH.

Application deadline: February 19, 2021, 11 p.m. CST



FUNDED BY NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES GRANT UT2GMI30174

PROMOTION





PITCH COMPETITION STUDENT STAR

CONGRATULATIONS **CRYSTAL JAMISON**



NOW ACCEPTING APPLICATIONS FOR SPR' 21



PITCH COMPETITION 1ST PLACE WINNER

CONGRATULATIONS

DR. SHAN YANG



RATORNETWORK.COM/ENRICH CCEPTING APPLICATIONS FOR SPR' 21



PITCH COMPETITION 3RD PLACE WINNER

CONGRATULATIONS DR. MARICICA PACURARI



XLERATORNETWORK.COM/ENRICH NOW ACCEPTING APPLICATIONS FOR SPR' 21



PITCH COMPETITION 2ND PLACE WINNER

CONGRATULATIONS DR. NICHOLAS HILL



XLERATORNETWORK.COM/ENRICH NOW ACCEPTING APPLICATIONS FOR SPR' 21




PITCH COMPETITION COACHES CHOICE

CONGRATULATIONS SHELIA MALONE



XI EDATORNETWORK COM/ENDICH NOW ACCEPTING APPLICATIONS FOR SPR' 21


EnRICH Video



Questions?

ncats.nih.gov/smallbusiness

NCATS-SBIRSTTR@mail.nih.gov







THANK YOU



